Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
Fms-like tyrosine kinase 3 (FLT3) plays an important role in hematopoietic differentiation, and constitutively active FLT3 mutant proteins contribute to the development of acute myeloid leukemia. Little is known about the protein-tyrosine phosphatases (PTP) affecting the signaling activity of FLT3. To identify such PTP, myeloid cells expressing wild type FLT3 were infected with a panel of lentiviral pseudotypes carrying shRNA expression cassettes targeting different PTP. Out of 20 PTP tested, expressed in hematopoietic cells, or presumed to be involved in oncogenesis or tumor suppression, DEP-1 (PTPRJ) was identified as a PTP negatively regulating FLT3 phosphorylation and signaling. Stable 32D myeloid cell lines with strongly reduced DEP-1 levels showed site-selective hyperphosphorylation of FLT3. In particular, the sites pTyr-589, pTyr-591, and pTyr-842 involved in the FLT3 ligand (FL)-mediated activation of FLT3 were hyperphosphorylated the most. Similarly, acute depletion of DEP-1 in the human AML cell line THP-1 caused elevated FLT3 phosphorylation. Direct interaction of DEP-1 and FLT3 was demonstrated by "substrate trapping" experiments showing association of DEP-1 D1205A or C1239S mutant proteins with FLT3 by co-immunoprecipitation. Moreover, activated FLT3 could be dephosphorylated by recombinant DEP-1 in vitro. Enhanced FLT3 phosphorylation in DEP-1-depleted cells was accompanied by enhanced FLT3-dependent activation of ERK and cell proliferation. Stable overexpression of DEP-1 in 32D cells and transient overexpression with FLT3 in HEK293 cells resulted in reduction of FL-mediated FLT3 signaling activity. Furthermore, FL-stimulated colony formation of 32D cells expressing FLT3 in methylcellulose was induced in response to shRNA-mediated DEP-1 knockdown. This transforming effect of DEP-1 knockdown was consistent with a moderately increased activation of STAT5 upon FL stimulation but did not translate into myeloproliferative disease formation in the 32D-C3H/HeJ mouse model. The data indicate that DEP-1 is negatively regulating FLT3 signaling activity and that its loss may contribute to but is not sufficient for leukemogenic cell transformation.
Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Friedrich Schiller University, Jena, Germany.
Deepika
D
Arora
Sabine
S
Stopp
Sylvia-Annette
SA
Böhmer
Julia
J
Schons
Rinesh
R
Godfrey
Kristina
K
Masson
Elena
E
Razumovskaya
Lars
L
Rönnstrand
Simone
S
Tänzer
Reinhard
R
Bauer
Frank-D
FD
Böhmer
Jörg P
JP
Müller
D019943:Amino Acid Substitution; D000818:Animals; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D055785:Gene Knockdown Techniques; D057809:HEK293 Cells; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D020125:Mutation, Missense; D010766:Phosphorylation; D054631:Receptor-Like Protein Tyrosine Phosphatases, Class 3 / Q000235:genetics / Q000378:metabolism; D050799:STAT5 Transcription Factor / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics / Q000378:metabolism*
D050799:STAT5 Transcription Factor; C497970:FLT3 protein, human; C497971:Flt3 protein, mouse; D051941:fms-Like Tyrosine Kinase 3; C486288:PTPRJ protein, human; D054631:Receptor-Like Protein Tyrosine Phosphatases, Class 3
Blood. 2003 Jul 15;102(2):646-51
12663439
Nat Rev Cancer. 2003 Sep;3(9):650-65
12951584
Int J Hematol. 2005 Aug;82(2):93-9
16146838
Blood. 2000 Dec 1;96(12):3907-14
11090077
J Biol Chem. 2009 Aug 14;284(33):22048-22058
19494114
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Blood. 2006 Jan 1;107(1):293-300
16150941
Brain Pathol. 2011 Jul;21(4):405-18
21091576
Blood. 2002 Sep 1;100(5):1532-42
12176867
Blood. 2005 Jan 1;105(1):335-40
15345593
Blood. 2003 Apr 15;101(8):3164-73
12468433
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1680-5
9050838
Exp Hematol. 2003 Nov;31(11):1007-14
14585362
Cancer Cell. 2002 Jun;1(5):421-32
12124172
Blood. 2005 Jun 15;105(12):4792-9
15718420
Clin Cancer Res. 2008 Jul 15;14(14):4437-45
18628457
Mol Cell Biol. 2009 Jan;29(1):241-53
18936167
Blood. 2005 Jul 1;106(1):265-73
15769897
J Biol Chem. 1999 Sep 10;274(37):26378-86
10473595
Nat Rev Cancer. 2006 Apr;6(4):307-20
16557282
FASEB J. 2007 Feb;21(2):523-34
17158785
J Virol. 1998 Nov;72(11):8463-71
9765382
Blood. 2009 Apr 9;113(15):3568-76
19204327
Curr Pharm Des. 2004;10(16):1867-83
15180525
Blood. 2006 Aug 15;108(4):1339-45
16627759
J Cell Biol. 2003 May 26;161(4):793-804
12771128
Leukemia. 1996 Dec;10(12):1911-8
8946930
Blood. 2006 Sep 1;108(5):1542-50
16684964
Mol Cell. 2004 Jan 30;13(2):169-78
14759363
Leukemia. 2008 Oct;22(10):1945-8
18368066
Cancer Cell. 2007 Dec;12(6):501-13
18068628
Mol Cell Biol. 2004 Mar;24(5):2190-201
14966296
Mol Cell Biol. 2005 May;25(9):3690-703
15831474
Curr Biol. 2009 Nov 17;19(21):1788-98
19836242
Hematology Am Soc Hematol Educ Program. 2006;:178-84
17124058
J Virol. 2002 Feb;76(3):1488-95
11773421
Oncogene. 2003 Jul 3;22(27):4175-85
12833140
Exp Hematol. 2009 Aug;37(8):979-89
19477218
Trends Cell Biol. 2001 Jun;11(6):258-66
11356362
Mol Cell. 2009 Oct 23;36(2):326-39
19854140
Genes Dev. 2005 Jun 1;19(11):1328-40
15901674
J Biol Chem. 2003 Feb 21;278(8):5728-35
12475979
Blood. 2002 Jun 15;99(12):4326-35
12036858
Immunity. 2008 Feb;28(2):183-96
18249142